NCT00525889View on ClinicalTrials.gov

Proleukin and Rapamune in Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2013

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

IL-2

Administered by subcutaneous injection at a dose of 4.5x10\^6 IU/day, three times weekly for 28 days starting on day 0.

DRUG

Rapamycin

Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.

Trial Locations (3)

10032

Naomi Berrie Diabetes Center, Columbia University, New York

97239

Oregon Health Sciences University, Portland

98101

Benaroya Research Institute, Seattle

All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00525889 - Proleukin and Rapamune in Type 1 Diabetes | Biotech Hunter | Biotech Hunter